J.C.-H. Yang

ORCID: 0009-0009-5159-587X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • HER2/EGFR in Cancer Research
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Cancer therapeutics and mechanisms
  • Lung Cancer Diagnosis and Treatment
  • Gastric Cancer Management and Outcomes
  • Peptidase Inhibition and Analysis
  • Cancer Immunotherapy and Biomarkers
  • Caching and Content Delivery
  • Recommender Systems and Techniques
  • Advanced Breast Cancer Therapies
  • RNA modifications and cancer
  • Quinazolinone synthesis and applications
  • Radiopharmaceutical Chemistry and Applications
  • Advanced Graph Neural Networks
  • Gastrointestinal Tumor Research and Treatment
  • Cell Adhesion Molecules Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • PI3K/AKT/mTOR signaling in cancer
  • Ovarian cancer diagnosis and treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Chronic Lymphocytic Leukemia Research
  • Extracellular vesicles in disease

National Taiwan University
2012-2024

Baidu (China)
2023-2024

National Taiwan University Hospital
2006-2023

Shanghai Pulmonary Hospital
2006

Chinese University of Hong Kong
2006

Guangdong Provincial People's Hospital
2006

Shanghai Chest Hospital
2006

Despite sharing similar tumor biology to other epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) tumors, no targeted therapies have been approved for NSCLC harboring EGFR Exon 20 insertion mutations (Exon20ins). The standard of care remains platinum-based chemotherapy the front-line, with clear subsequent options available. Amivantamab (JNJ-61186372) is a novel, fully human EGFR-MET bispecific antibody immune cell-directing activity that targets activating and...

10.1016/j.jtho.2021.01.284 article EN publisher-specific-oa Journal of Thoracic Oncology 2021-03-01

While having been used widely for large-scale recommendation and online advertising, the Graph Neural Network (GNN) has demonstrated its representation learning capacity to extract embeddings of nodes edges through passing, transforming, aggregating information over graph. In this work, we propose PGLBox1 - a multi-GPU graph framework based on PaddlePaddle [24], incorporating with optimized storage, computation, communication strategies, train deep GNNs web-scale graphs recommendation....

10.1145/3580305.3599885 article EN Proceedings of the 28th ACM SIGKDD Conference on Knowledge Discovery and Data Mining 2023-08-04

Tolerable therapies are needed for previously treated pts with advanced EGFRm NSCLC. The ph 2 HERTHENA-Lung01 trial (NCT04619004) showed meaningful efficacy and a manageable safety profile. To extend these observations, we present data an additional 6 mo of follow-up. Pts (N=225) EGFR TKI platinum-based chemotherapy received HER3-DXd 5.6 mg/kg IV Q3W. Median treatment (TX) duration was 5.5 (range, 0.7-23.7) mo. 224 (99.6%) had any-grade (G) TEAEs; 147 (65.3%) G ≥3. Most common any-G TEAEs...

10.1016/j.esmoop.2024.102590 article EN cc-by-nc-nd ESMO Open 2024-03-01

Graph Neural Networks (GNNs) have become critical in various domains such as online advertising but face scalability challenges due to the growing size of graph data, leading needs for advanced distributed GPU computation strategies across multiple nodes. This paper presents PGLBox-Cluster, a robust learning framework constructed atop PaddlePaddle platform, implemented efficiently process graphs comprising billions nodes and edges. Through strategic partitioning model, node attributes, data...

10.1145/3627673.3680018 article EN 2024-10-20
Coming Soon ...